

Company Overview

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers. We have three core technologies, all of which are based on discoveries made by Dr. Waldemar Priebe and his team at The University of Texas MD Anderson Cancer Center. Our clinical stage drugs are Annamycin, a Next Generation Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors.

Our Next Generation Anthracycline, Annamycin, is unlike any currently approved anthracyclines, as it is designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin has preliminary clinical data suggesting its potential to become the first successful therapy suitable for the majority of relapsed or refractory AML patients and is currently in two Phase I/II clinical trials.

WP1066 is one of several Immune/Transcription Modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1 α . These transcription factors are widely sought targets that may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors.

We are also developing new prodrugs to exploit the potential uses of inhibitors of glycolysis. Our lead Metabolism/Glycosylation Inhibitor compound, WP1122, provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells. New research also points to the potential for the glucose decoy (2-DG) within WP1122 to be capable of enhancing the usefulness of checkpoint inhibitors.

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia

Jul 13 2021, 8:35 AM EDT

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

Jun 21 2021, 8:35 AM EDT

Moleculin Announces Inclusion in the Russell 2000® Index

Jun 15 2021, 9:05 AM EDT

Stock Overview

Symbol	MBRX
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week	\$ - \$

Investor Relations

JTC Team, LLC.
Jenene Thomas
T: 833-475-8247
mbrx@jtcir.com

Management Team

Walter V. Klemp

Founder, President, Chairman, CEO, and Business Advisory Board Member

Donald Picker, PhD

Chief Scientific Officer

Robert Shepard, MD, FACP

Chief Medical Officer - Hematology

Sandra Silberman, MD, PhD

Chief Medical Officer - New Products

Jonathan P. Foster

Chief Financial Officer

Moleculin Biotech, Inc.

5300 Memorial Drive
Suite 950
Houston, TX 77007

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.